Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.
Pakeeran SiriratnamPaul SanfilippoAnneke Van Der WaltSifat SharminYi Chao FoongWei Zhen YehChao ZhuSamia Joseph KhouryTunde CsepanyBarbara WillekensMasoud EtemadifarSerkan OzakbasPetra NytrovaAyse AltintasAbdullah Al-AsmiBassem YamoutGuy LaureysFrancesco PattiMagdolna SimoAndrea SurcinelliMatteo FoschiPamela A McCombeRaed AlroughaniJosé Luis Sánchez-MenoyoRecai TurkogluAysun SoysalJeanette Lechner ScottTomas KalincikHelmut ButzkuevenVilija G JokubaitisSaif HudaMastura Monifnull nullPublished in: Journal of neurology, neurosurgery, and psychiatry (2024)
Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus.
Keyphrases